Walvax Biotechnology Co., Ltd. vaccine candidate (SARS-CoV-2 mRNA vaccine)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Walvax Biotechnology Co., Ltd. vaccine candidate (SARS-CoV-2 mRNA vaccine), covering 2021-11-18 to 2021-11-18. Get the full timeline:
Most recent: Clinical Trial Update: A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above [Phase 3]